22 reports

  • Number of Seasonal Influenza Drugs in Early Stage Development, by Therapeutic Class
  • PIPELINE PRODUCTS - EARLY-STAGE PIPELINE

She is a co-inventor on many issued US patents and applications related to projects on cell and gene therapies.

  • Influenza
  • United States
  • Roche Group
  • Sanofi S.A.
  • Shionogi & Co., Ltd.
  • R&D Progress
  • INFLUENZAVIRUS B INFECTIONS - PIPELINE BY INOVIO PHARMACEUTICALS INC, H2 2018

Gene therapy acts by stimulating immune response.

  • Influenza
  • Japan
  • United States
  • World
  • Product Initiative
  • R&D Progress
  • INFLUENZAVIRUS B INFECTIONS - PIPELINE BY INOVIO PHARMACEUTICALS INC, H1 2018

GENE THERAPY ACTS BY STIMULATING IMMUNE RESPONSE.

  • Influenza
  • Australia
  • United States
  • World
  • Product Initiative
  • ORYGEN BIOTECNOLOGIA ENTERS INTO LICENSING AGREEMENT WITH PROTEIN SCIENCES FOR FLUBLOK
  • SANOFI ACQUIRES PROTEIN SCIENCES

Under the terms of the agreement, uniQure will pay an upfront payment and one-time milestone payment to Protein Sciences.

  • Influenza
  • Vaccine
  • United States
  • M&A
  • Protein Sciences Corporation

Global Influenza Market: Size, Trends & Forecasts (2018-2022) NOVEMBER 2018 ##.

  • Influenza
  • Molecular Diagnostics
  • United States
  • World
  • Market Size
  • GENENTECH INC
  • EPIVAX INC

The company offers its development services for viral gene therapy, cell therapy, mRNA, gene editing, monoclonal antibodies, non-viral gene therapy.

  • Influenza
  • Monoclonal Antibody
  • Vaccine
  • United States
  • Product Initiative

Equels will be presenting and meeting one-on-one with investors.

  • Influenza
  • Pharmaceutical
  • United States
  • World
  • Hemispherx Biopharma, Inc.
  • INFLUENZA A VIRUS, H3N2 SUBTYPE INFECTIONS - PIPELINE BY SANOFI PASTEUR SA, H2 2018
  • INFLUENZA A VIRUS, H3N2 SUBTYPE INFECTIONS - PIPELINE BY SANOFI, H2 2018

SANOFI PASTEUR SA Sarepta Therapeutics Inc (Sarepta) is discovers and develops unique RNA-targeted therapeutics, gene therapy and other genetic medicine approaches to treat rare neuromuscular diseases.

  • Influenza
  • United States
  • World
  • Product Initiative
  • BiondVax Pharmaceuticals Ltd.
  • EMERGENT BIOSOLUTIONS INC
  • INFLUENZA A VIRUS, H1N1 SUBTYPE INFECTIONS - PIPELINE BY TECHNOVAX INC, H2 2018

The company offers its development services for viral gene therapy, cell therapy, mRNA, gene editing, monoclonal antibodies, non-viral gene therapy.

  • Influenza
  • Therapy
  • Vaccine
  • United States
  • Product Initiative
  • SEP 17, 2018: INOVIO DEVELOPS NOVEL H3N2 INFLUENZA DNA VACCINE THAT GENERATES CROSS-REACTIVE RESPONSES AND PROVIDES COMPLETE PROTECTION AGAINST LETHAL PRECLINICAL CHALLENGES
  • Influenza A Virus, H3N2 Subtype Infections - Companies Involved in Therapeutics Development

NV-INF-##).

  • Influenza
  • Vaccine
  • United States
  • Product Initiative
  • BiondVax Pharmaceuticals Ltd.
  • INFLUENZA A VIRUS, H7N9 SUBTYPE INFECTIONS - PIPELINE BY OLOGY BIOSERVICES INC, H1 2018
  • INFLUENZA A VIRUS, H7N9 SUBTYPE INFECTIONS - PIPELINE BY NANOVIRICIDES INC, H1 2018

The company conducts research in the areas of medical science and pharmaceutical technology such as polymeric micelles, multi-specific multi-targeting, anti-sense DNA, siRNA, ribozymes and gene therapy.

  • Influenza
  • Vaccine
  • United States
  • Company Operations
  • NanoViricides, Inc.
  • INFLUENZA A VIRUS, H7N9 SUBTYPE INFECTIONS - PIPELINE BY MODERNA THERAPEUTICS INC, H2 2017
  • MEDIGEN VACCINE BIOLOGICS CORP

The company conducts research in the areas of medical science and pharmaceutical technology such as polymeric micelles, multi-specific multi-targeting, anti-sense DNA, siRNA, ribozymes and gene therapy.

  • Influenza
  • United States
  • Company
  • Product Initiative
  • NanoViricides, Inc.
  • CUREVAC AG
  • INFLUENZA A VIRUS, H5N1 SUBTYPE INFECTIONS - PIPELINE BY FLUGEN INC, H1 2019

The company offers customized alliances for the development and production of gene therapy vectors and engineered vaccine.

  • Influenza
  • United States
  • World
  • Product Initiative
  • Hemispherx Biopharma, Inc.
  • NANOVIRICIDES INC
  • INFLUENZA A VIRUS, H5N1 SUBTYPE INFECTIONS - PIPELINE BY NANOVIRICIDES INC, H2 2018

The target Influenza viruses are Influenza A viruses, the transmembrane proteins are comprised of one or more different HA subtypes ## -## and / or NA subtypes ## -## ##.

  • Influenza
  • Vaccine
  • United States
  • Product Initiative
  • BiondVax Pharmaceuticals Ltd.
  • INFLUENZA A VIRUS, H1N1 SUBTYPE INFECTIONS - PIPELINE BY EPIVAX INC
  • INFLUENZA A VIRUS, H1N1 SUBTYPE INFECTIONS - PIPELINE BY ETUBICS CORP

IT ALSO OFFERS GENE THERAPIES FOR POMPE DISEASE AND AUDITORY DISORDERS.

  • Influenza
  • Pathology
  • Pharmaceutical
  • Vaccine
  • Product Initiative
  • 5.4.11 MODERNA THERAPEUTICS INC
  • INFLUENZA A VIRUS, H5N1 SUBTYPE INFECTIONS - PIPELINE BY NANOVIRICIDES INC

IT ALSO OFFERS GENE THERAPIES FOR POMPE DISEASE AND AUDITORY DISORDERS.

  • Influenza
  • Pharmaceutical
  • Vaccine
  • Product Initiative
  • Sanofi S.A.

ALS, also known as Lou Gehrig' s, is one such disease.

  • Infectious Disease
  • Influenza
  • Pharmaceutical
  • Therapy
  • Vaccine

NanoViricides also conducts research in the areas of medical science and pharmaceutical technology such as polymeric micelles, multispecific multi-targeting, anti-sense DNA, siRNA, ribozymes, and gene therapy.

  • Infectious Disease
  • Influenza
  • Therapy
  • Vaccine
  • Hemispherx Biopharma, Inc.
  • VH-244 - DRUG PROFILE

The Company also announced the preliminary results were presented at The Cancer Vaccines and Gene Therapy Meeting.

  • Influenza
  • Monoclonal Antibody
  • Vaccine
  • United States
  • Hemispherx Biopharma, Inc.
  • H1N1 INFECTION - PIPELINE BY ETUBICS CORPORATION, H1 2016

It also offers gene therapies for pompe disease and auditory disorders.

  • Influenza
  • Research And Development
  • Vaccine
  • United States
  • Company Operations

NV-INF-##).

  • Influenza
  • Vaccine
  • United States
  • Company Operations
  • NanoViricides, Inc.

Its broad pipeline is built on a legacy of innovation in bleeding disorders and immunology, and is expanding to address unmet medical needs in niche areas of oncology, as well as technology platforms such as gene therapy.

  • Influenza
  • Vaccine
  • United States
  • Company Operations
  • Nanotherapeutics, Inc.